|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||2.46 / 6.18|
Study results will help to define the effective dose range of nicotinamide riboside (NR) in humans when taken daily, over eight weeks.
Levi & Korsinsky announces it has commenced an investigation of ChromaDex Corporation ("ChromaDex" or the "Company") (NASDAQ:CDXC) concerning possible violations of federal securities laws.
Goldberg Law PC ( http://www.Goldberglawpc.
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of ChromaDex Corporation (NASDAQ:CDXC) resulting from allegations that ChromaDex may...
New published study shows a unique form of vitamin B3, nicotinamide riboside, may help with weight gain and glycemic control as well as protect nerves from diabetic damage
Company Will Host Investor Conference Call on Monday, May 16, 2016
- Mayo Clinic, University of Minnesota and ChromaDex to Collaborate on Study -
Company Will Host Investor Conference Call on Monday, March 21, 2016